Vanguard Fiduciary Trust
PLX icon

Vanguard Fiduciary Trust’s Protalix BioTherapeutics PLX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Buy
70,277
+6,926
+11% +$14.7K ﹤0.01% 3632
2026
Q1 		$137K Buy
+63,351
New +$157K ﹤0.01% 3633

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Fiduciary Trust's PLX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Protalix BioTherapeutics (PLX) stake by 11% in Q2 2026, buying an estimated $14.7K and bringing the position to 70,277 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #3632.

Vanguard Fiduciary Trust first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Vanguard Fiduciary Trust held 70,277 shares of Protalix BioTherapeutics worth $164K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 6,926 Protalix BioTherapeutics shares in Q2 2026, an estimated $14.7K.
  • Protalix BioTherapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3632 holding.
  • Vanguard Fiduciary Trust first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.